Similar articles

• Intravenous pamidronate for myeloma bone disease: can the dose be lowered?

  Terpos E, Dimopoulos MA. Terpos E, et al. Lancet Oncol. 2010 Oct;11(10):913-4. doi: 10.1016/S1470-2045(10)70227-8. Lancet Oncol. 2010. PMID: 20863760 No abstract available.
• Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.

  Gimsing P, Carlson K, Turesson I, Fayers P, Waage A, Vangsted A, Mylin A, Gluud C, Juliusson G, Gregersen H, Hjorth-Hansen H, Nesthus I, Dahl IM, Westin J, Nielsen JL, Knudsen LM, Ahlberg L, Hjorth M, Abildgaard N, Andersen NF, Linder O, Wisløff F. Gimsing P, et al. Lancet Oncol. 2010 Oct;11(10):973-82. doi: 10.1016/S1470-2045(10)70198-4. Lancet Oncol. 2010. PMID: 20863761 Clinical Trial.
• Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone.

  Tosi P, Zamagni E, Cangini D, Tacchetti P, Di Raimondo F, Catalano L, D'Arco A, Ronconi S, Cellini C, Offidani M, Perrone G, Ceccolini M, Brioli A, Tura S, Baccarani M, Cavo M. Tosi P, et al. Blood. 2006 Dec 1;108(12):3951-2. doi: 10.1182/blood-2006-07-033571. Blood. 2006. PMID: 17114572 Clinical Trial. No abstract available.
• The changing treatment paradigm in patients with newly diagnosed multiple myeloma: implications for nursing.

  Tariman JD, Estrella SM. Tariman JD, et al. Oncol Nurs Forum. 2005 Nov 3;32(6):E127-38. doi: 10.1188/05.ONF.E127-E138. Oncol Nurs Forum. 2005. PMID: 16270103 Review.
• Bisphosphonates--role in cancer therapies.

  Mehrotra B. Mehrotra B. J Oral Maxillofac Surg. 2009 May;67(5 Suppl):19-26. doi: 10.1016/j.joms.2009.01.012. J Oral Maxillofac Surg. 2009. PMID: 19371811 Review. No abstract available.